06c1c8ee-6564-46fe-9989-dbf4fbf086fe_1531776 - ... -

Prevents the FDA from delaying the approval of a generic drug unless a delay is necessary to protect public health.

To curb potential abuse, the U.S. Congress passed of the Federal Food, Drug, and Cosmetic Act. This law:

Under FDA regulations, any individual or entity can petition the agency to take (or refrain from taking) a specific administrative action. In the context of pharmaceuticals, these are often used to raise concerns about the safety or bioequivalence of a pending generic drug application (ANDA). 2. The "Sham" Petition Concern

The core issue discussed in the SSRN study (ID 1531776) is whether brand-name manufacturers use these filings strategically.

Prevents the FDA from delaying the approval of a generic drug unless a delay is necessary to protect public health.

To curb potential abuse, the U.S. Congress passed of the Federal Food, Drug, and Cosmetic Act. This law:

Under FDA regulations, any individual or entity can petition the agency to take (or refrain from taking) a specific administrative action. In the context of pharmaceuticals, these are often used to raise concerns about the safety or bioequivalence of a pending generic drug application (ANDA). 2. The "Sham" Petition Concern

The core issue discussed in the SSRN study (ID 1531776) is whether brand-name manufacturers use these filings strategically.

MONITOR YOUR WEB APPLICATION PERFORMANCE

Gain availability and performance insights with Pingdom – a comprehensive web application performance and digital experience monitoring tool.

START YOUR FREE 30-DAY TRIAL
Start monitoring for free